Acute Application of Pegvisomant and Octreotide in Acromegaly
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate the efficacy of an acute additional application of
the somatostatin analogue octreotide 100µg s.c. or the dopamine agonist cabergoline 0.5mg
p.o. to the receptor antagonist pegvisomant during a 6 or 9 hour profile on reducing
endogenous growth hormone in patients with acromegaly on stable pegvisomant therapy.